Ross Clark Ross Clark

Will the speculative vaccine shopping spree ever end?

English team attempting to develop a vaccine for Covid-19, Picture: Getty

Somewhere, possibly in the land of big sheds, just off the M1 in Leicestershire, must be a burgeoning NHS surplus store. Its shelves will be groaning with ventilators and testing kits which turned out not to work, surgical gloves, bibs and masks which turned out to be defective – and quite possibly, in months to come, with millions of shots of vaccines which won’t be able to be used.

It was announced this morning that the government has signed up for 60 million doses of a vaccine being developed by GSK and Sanofi – although the financial details of the deal were not released. GSK says the vaccine will enter clinical trials this autumn and will – possibly – be ready for manufacture in the second half of 2021. This order is in addition to the 100 million shots of Oxford/Astra Zeneca vaccine, 30 million of a vaccine being developed by BioNtech and Pfizer and 60 million of a vaccine being developed by Valneva. That is a total of 250 million shots of vaccine for a country of 65 million people – Britain is not going to be a safe place in the coming months for anyone with a needle phobia.

Britain is not going to be a safe place in the coming months for anyone with a needle phobia

It is not necessarily going to end here, either. There are around 140 other Covid-19 vaccines being developed around the world. Given that the government still has no real idea of which will work, if any, it is hard to see at what point ministers and officials draw the line and stop this speculative vaccine shopping spree.

It all comes in spite of warnings by Kate Bingham, the chair of the government’s Vaccine Taskforce that ‘the fact remains we may never get a vaccine and if we do get one, we have to be prepared that it may not be a vaccine which prevents getting the virus, but rather one that reduces symptoms.’

Already a subscriber? Log in

Keep reading with a free trial

Subscribe and get your first month of online and app access for free. After that it’s just £1 a week.

There’s no commitment, you can cancel any time.

Or

Unlock more articles

REGISTER

Comments

Don't miss out

Join the conversation with other Spectator readers. Subscribe to leave a comment.

Already a subscriber? Log in